Exploitation of the notch signaling pathway as a novel target for cancer therapy

Anticancer Research

Volumn 28, Issue 6 A, 2008, Pages 3621-3630

  Wang, Zhiwei ^a   Li, Yiwei ^a   Banerjee, Sanjeev ^a   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Notch; Review; Signal pathway

Indexed keywords

BETA CATENIN; CURCUMIN; GAMMA SECRETASE INHIBITOR; GENISTEIN; HERBACEOUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; JAGGED1; MAMMALIAN TARGET OF RAPAMYCIN; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; RAPAMYCIN; RAS PROTEIN; RESVERATROL; SONIC HEDGEHOG PROTEIN; TUMOR MARKER; WNT PROTEIN;

APOPTOSIS; B CELL LYMPHOMA; CANCER GROWTH; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL FATE; CELL KILLING; CELL PROLIFERATION; CELL RENEWAL; CHINESE HERB; CROSS LINKING; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; DRUG TARGETING; GENE OVEREXPRESSION; GLIOMA; HUMAN; KAPOSI SARCOMA; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

ANIMALS; ANTICARCINOGENIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NEOPLASMS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 58149174376     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Miele L: Notch signaling. Clin Cancer Res 12: 1074-1079, 2006.
2. Miele L, Miao H and Nickoloff BJ: NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets 6: 313-323, 2006.
3. Okuyama R, Tagami H and Aiba S: Notch signaling: its role in epidermal homeostasis and in the pathogenesis of skin diseases. J Dermatol Sci 49: 187-194, 2008.
4. Wilson A and Radtke F: Multiple functions of Notch signaling in self-renewing organs and cancer. FEBS Lett 580: 2860-2868, 2006.
5. Miele L and Osborne B: Arbiter of differentiation and death: Notch signaling meets apoptosis. J Cell Physiol 181: 393-409, 1999.
6. Joutel A and Tournier-Lasserve E: Notch signalling pathway and human diseases. Semin Cell Dev Biol 9: 619-625, 1998.
7. Qi R, An H, Yu Y et al: Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res 63: 8323-8329, 2003.
8. Shou J, Ross S, Koeppen H, de Sauvage FJ and Gao WQ: Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res 61: 7291-7297, 2001.
9. Sriuranpong V, Borges MW, Ravi RK et al: Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Research 61: 3200-3205, 2001.
10. Miyamoto Y, Maitra A, Ghosh B et al: Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3: 565-576, 2003.
11. Koch U and Radtke F: Notch and cancer: a double-edged sword. Cell Mol Life Sci 64: 2746-2762, 2007.
12. Allenspach EJ, Maillard I, Aster JC and Pear WS: Notch signaling in cancer. Cancer Biol Ther 1: 466-476, 2002.
13. Bolos V, Grego-Bessa J and de la Pompa JL: Notch signaling in development and cancer. Endocr Rev 28: 339-363, 2007.
14. Chiaramonte R, Basile A, Tassi E et al: A wide role for NOTCH1 signaling in acute leukemia. Cancer Lett 219: 113-120, 2005.
15. Aster JC, Pear WS and Blacklow SC: Notch signaling in leukemia. Annu Rev Pathol 3: 587-613, 2008.
16. Reedijk M, Odorcic S, Chang L et al: High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Research 65: 8530-8537, 2005.
17. Zhu YM, Zhao WL, Fu JF et al: NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis. Clin Cancer Res 12: 3043-3049, 2006.
18. Santagata S, Demichelis F, Riva A et al: JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 64: 6854-6857, 2004.
19. Aggarwal BB: Nuclear factor-kappaB: the enemy within. Cancer Cell 6: 203-208, 2004.
20. Sarkar FH and Li Y: NF-kappaB: a potential target for cancer chemoprevention and therapy. Front Biosci 13: 2950-2959, 2008.
21. Oswald F, Liptay S, Adler G and Schmid RM: NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa. Mol Cell Biol 18: 2077-2088, 1998.
22. Jang MS, Miao H, Carlesso N et al: Notch-1 regulates cell death independently of differentiation in murine erythroleukemia cells through multiple apoptosis and cell cycle pathways. J Cell Physiol 199: 418-433, 2004.
23. Nickoloff BJ, Qin JZ, Chaturvedi V, Denning MF, Bonish B and Miele L: Jagged-1-mediated activation of notch signaling induces complete maturation of human keratinocytes through NF-kappaB and PPARgamma. Cell Death Differ 9: 842-855, 2002.
24. Wang Y, Chan SL, Miele L et al: Involvement of Notch signaling in hippocampal synaptic plasticity. Proc Natl Acad Sci USA 101: 9458-9462, 2004.
25. Vilimas T, Mascarenhas J, Palomero T et al: Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 13: 70-77, 2007.
26. Fernandez-Majada V, Aguilera C, Villanueva A et al: Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer. Proc Natl Acad Sci USA 104: 276-281, 2007.
27. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y and Sarkar FH: Down-regulation of Notch-1 inhibits invasion by inactivation of nuclear factor-{kappa}B, vascular endothelial growth factor and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 66: 2778-2784, 2006.
28. Bash J, Zong WX, Banga S et al: Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors. EMBO J 18: 2803-2811, 1999.
29. Moran ST, Cariappa A, Liu H et al: Synergism between NF-kappa B1/p50 and Notch2 during the development of marginal zone B lymphocytes. J Immunol 179: 195-200, 2007.
30. Osipo C, Golde TE, Osborne BA and Miele LA: Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest 88: 11-17, 2008.
31. Crowell JA, Steele VE and Fay JR: Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther 6: 2139-2148, 2007.
32. Cheng GZ, Park S, Shu S et al: Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets 8: 2-6, 2008.
33. Tokunaga E, Oki E, Egashira A et al: Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 8: 27-36, 2008.
34. Brunet A, Bonni A, Zigmond MJ et al: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868, 1999.
35. Cardone MH, Roy N, Stennicke HR et al: Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-1321, 1998.
36. Rommel C, Clarke BA, Zimmermann S et al: Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286: 1738-1741, 1999.
37. Kane LP, Mollenauer MN, Xu Z, Turck CW and Weiss A: Akt-dependent phosphorylation specifically regulates Cot induction of NF-kappa B-dependent transcription. Mol Cell Biol 22: 5962-5974, 2002.
38. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM and Donner DB: NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401: 82-85, 1999.
39. Liu ZJ, Xiao M, Balint K et al: Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res 66: 4182-4190, 2006.
40. Palomero T, Dominguez M and Ferrando AA: The role of the PTEN/AKT pathway in NOTCH1-induced leukemia. Cell Cycle 7: 965-970, 2008.
41. Gutierrez A and Look AT: NOTCH and PI3K-AKT pathways intertwined. Cancer Cell 12: 411-413, 2007.
42. Palomero T, Sulis ML, Cortina M et al: Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 13: 1203-1210, 2007.
43. Veeraraghavalu K, Subbaiah VK, Srivastava S, Chakrabarti O, Syal R and Krishna S: Complementation of human papillomavirus type 16 E6 and E7 by Jagged1-specific Notch1-phosphatidylinositol 3-kinase signaling involves pleiotropic oncogenic functions independent of CBF1;Su(H);Lag-1 activation. J Virol 79: 7889-7898, 2005.
44. Androutsellis-Theotokis A, Leker RR, Soldner F et al: Notch signalling regulates stem cell numbers in vitro and in vivo. Nature 442: 823-826, 2006.
45. Chan SM, Weng AP, Tibshirani R, Aster JC and Utz PJ: Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 110: 278-286, 2007.
46. Mungamuri SK, Yang X, Thor AD and Somasundaram K: Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. Cancer Research 66: 4715-4724, 2006.
47. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C and Blenis J: mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24: 200-216, 2004.
48. Chiang GG and Abraham RT: Targeting the mTOR signaling network in cancer. Trends Mol Med 13: 433-442, 2007.
49. Purow BW, Sundaresan TK, Burdick MJ et al: Notch-1 regulates transcription of the epidermal growth factor receptor through p53. Carcinogenesis 29: 918-925, 2008.
50. Zhang YW, Wang R, Liu Q, Zhang H, Liao FF and Xu H: Presenilin/gamma- secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci USA 104: 10613-10618, 2007.
51. Wang Z, Sengupta R, Banerjee S et al: Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. Cancer Research 66: 7653-7660, 2006.
52. Kong D, Banerjee S, Huang W et al: Mammalian target of rapamycin repression by 3,3′-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells. Cancer Res 68: 1927-1934, 2008.
53. Wang Z, Kong D, Banerjee S et al: Down-regulation of platelet-derived growth factor-D inhibits cell growth and angiogenesis through inactivation of Notch-1 and nuclear factor-kappaB signaling. Cancer Res 67: 11377-11385, 2007.
54. Fredriksson L, Li H and Eriksson U: The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 15: 197-204, 2004.
55. Reigstad LJ, Varhaug JE and Lillehaug JR: Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family. FEBS J 272: 5723-5741, 2005.
56. Li H, Fredriksson L, Li X and Eriksson U: PDGF-D is a potent transforming and angiogenic growth factor. Oncogene 22: 1501-1510, 2003.
57. Bongarzone ER, Byravan S, Givogri MI, Schonmann V and Campagnoni AT: Platelet-derived growth factor and basic fibroblast growth factor regulate cell proliferation and the expression of notch-1 receptor in a new oligodendrocyte cell line. J Neurosci Res 62: 319-328, 2000.
58. Claxton S and Fruttiger M: Periodic Delta-like 4 expression in developing retinal arteries. Gene Expr Patterns 5: 123-127, 2004.
59. Ingram WJ, McCue KI, Tran TH, Hallahan AR and Wainwright BJ: Sonic hedgehog regulates Hes1 through a novel mechanism that is independent of canonical Notch pathway signalling. Oncogene 27: 1489-1500, 2008.
60. Pepinsky RB, Rayhorn P, Day ES et al: Mapping sonic hedgehog-receptor interactions by steric interference. J Biol Chem 275: 10995-11001, 2000.
61. Nicolas M, Wolfer A, Raj K et al: Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 33: 416-421, 2003.
62. Katoh M: Dysregulation of stem cell signaling network due to germline mutation, SNP, helicobacter pylori infection, epigenetic change and genetic alteration in gastric cancer. Cancer Biol Ther 6: 832-839, 2007.
63. Yokota N, Mainprize TG, Taylor MD et al: Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. Oncogene 23: 3444-3453, 2004.
64. Dakubo GD, Mazerolle CJ and Wallace VA: Expression of Notch and Wnt pathway components and activation of Notch signaling in medulloblastomas from heterozygous patched mice. J Neurooncol 79: 221-227, 2006.
65. Hallahan AR, Pritchard JI, Hansen S et al: The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res 64: 7794-7800, 2004.
66. Nakamura T, Tsuchiya K and Watanabe M: Crosstalk between Wnt and Notch signaling in intestinal epithelial cell fate decision. J Gastroenterol 42: 705-710, 2007.
67. Proweller A, Tu L, Lepore JJ et al: Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Research 66: 7438-7444, 2006.
68. van Es JH, van Gijn ME, Riccio O et al: Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435: 959-963, 2005.
69. Duncan AW, Rattis FM, DiMascio LN et al: Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. Nat Immunol 6: 314-322, 2005.
70. Trowbridge JJ, Xenocostas A, Moon RT and Bhatia M: Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat Med 12: 89-98, 2006.
71. Blank U, Karlsson G and Karlsson S: Signaling pathways governing stem-cell fate. Blood 111: 492-503, 2008.
72. Sundaram MV: The love-hate relationship between Ras and Notch. Genes Dev 19: 1825-1839, 2005.
73. Stockhausen MT, Sjolund J and Axelson H: Regulation of the Notch target gene Hes-1 by TGFalpha-induced Ras/MAPK signaling in human neuroblastoma cells. Exp Cell Res 310: 218-228, 2005.
74. Fitzgerald K, Harrington A and Leder P: Ras pathway signals are required for notch-mediated oncogenesis. Oncogene 19: 4191-4198, 2000.
75. Weijzen S, Rizzo P, Braid M et al: Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 8: 979-986, 2002.
76. Kiaris H, Politi K, Grimm LM et al: Modulation of notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium. Am J Pathol 165: 695-705, 2004.
77. Kakarala M and Wicha MS: Cancer stem cells: implications for cancer treatment and prevention. Cancer J 13: 271-275, 2007.
78. Ohlstein B, Kai T, Decotto E and Spradling A: The stem cell niche: theme and variations. Curr Opin Cell Biol 16: 693-699, 2004.
79. Keith B and Simon MC: Hypoxia-inducible factors, stem cells and cancer. Cell 129: 465-472, 2007.
80. Rossi DJ, Jamieson CH and Weissman IL: Stems cells and the pathways to aging and cancer. Cell 132: 681-696, 2008.
81. Cariati M and Purushotham AD: Stem cells and breast cancer. Histopathology 52: 99-107, 2008.
82. Sakariassen PO, Immervoll H and Chekenya M: Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia 9: 882-892, 2007.
83. Lagasse E: Cancer stem cells with genetic instability: the best vehicle with the best engine for cancer. Gene Ther 15: 136-142, 2008.
84. Tang C, Ang BT and Pervaiz S: Cancer stem cell: target for anticancer therapy. FASEB J 21: 3777-3785, 2007.
85. Sales KM, Winslet MC and Seifalian AM: Stem cells and cancer: an overview. Stem Cell Rev 3: 249-255, 2007.
86. Styczynski J and Drewa T: Leukemic stem cells: from metabolic pathways and signaling to a new concept of drug resistance targeting. Acta Biochim Pol 54: 717-726, 2007.
87. Katoh M: Networking of WNT, FGF, Notch, BMP and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev 3: 30-38, 2007.
88. Phillips TM, Kim K, Vlashi E, McBride WH and Pajonk F: Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia 9: 1122-1129, 2007.
89. Farnie G and Clarke RB: Mammary stem cells and breast cancer - role of Notch signalling. Stem Cell Rev 3: 169-175, 2007.
90. Zhang XP, Zheng G, Zou L et al: Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells. Mol Cell Biochem 307: 101-108, 2008.
91. Fan X, Matsui W, Khaki L et al: Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Research 66: 7445-7452, 2006.
92. Gal H, Amariglio N, Trakhtenbrot L et al: Gene expression profiles of AML-derived stem cells; similarity to hematopoietic stem cells. Leukemia 20: 2147-2154, 2006.
93. Shih I and Wang TL: Notch signaling, gamma-secretase inhibitors and cancer therapy. Cancer Res 67: 1879-1882, 2007.
94. Sjolund J, Manetopoulos C, Stockhausen MT and Axelson H: The Notch pathway in cancer: differentiation gone awry. Eur J Cancer 41: 2620-2629, 2005.
95. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J and Sarkar FH: Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther 5: 483-493, 2006.
96. Rutz S, Janke M, Kassner N, Hohnstein T, Krueger M and Scheffold A: Notch regulates IL-10 production by T-helper 1 cells. Proc Natl Acad Sci USA 105: 3497-3502, 2008.
97. Sun J, Krawczyk CJ and Pearce EJ: Suppression of Th2 cell development by Notch ligands Delta1 and Delta4. J Immunol 180: 1655-1661, 2008.
98. O'Neil J, Calvo J, McKenna K et al: Activating Notch1 mutations in mouse models of T-ALL. Blood 107: 781-785, 2006.
99. Curry CL, Reed LL, Golde TE, Miele L, Nickoloff BJ and Foreman KE: Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 24: 6333-6344, 2005.
100. Zhang Y, Wang Z, Ahmed F, Banerjee S, Li Y and Sarkar FH: Down-regulation of Jagged-1 induces cell growth inhibition and S-phase arrest in prostate cancer cells. Int J Cancer 119: 2071-2077, 2006.
101. Barten DM, Meredith JE Jr, Zaczek R, Houston JG and Albright CF: Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity. Drugs R D 7: 87-97, 2006.
102. Wang Z, Zhang Y, Banerjee S, Li Y and Sarkar FH: Inhibition of nuclear factor kappaB activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int J Cancer 118: 1930-1936, 2006.
103. Wang Z, Zhang Y, Banerjee S, Li Y and Sarkar FH: Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 106: 2503-2513, 2006.
104. Zhang Z, Wang Y, Yao R et al: Cancer chemopreventive activity of a mixture of Chinese herbs (antitumor B) in mouse lung tumor models. Oncogene 23: 3841-3850, 2004.
105. Cecchinato V, Chiaramonte R, Nizzardo M et al: Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochem Pharmacol 74: 1568-1574, 2007.